ANAIS BRASILEIROS DE DERMATOLOGIA巴西皮肤病学纪事
ANAIS BRASILEIROS DE DERMATOLOGIA(英文缩写 AN BRAS DERMATOL),ISSN 0365-0596,eISSN 1806-4841,中文译名:巴西皮肤病学纪事 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-27 至 2026-09-27，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 2.113 | Q3 |
| 2022 | 1.700 | Q3 |
| 2023 | 2.600 | Q2 |
| 2024 | 3.600 | Q1 |
| 2025 | 4.400 | Q1 |
ANAIS BRASILEIROS DE DERMATOLOGIA 最新收录文献
-
1. Upadacitinib for refractory cutaneous disease in a patient with tif1γ-positive dermatomyositis.
PMID:日期:2026-09-04该文献暂无摘要。
-
7. The stigma-induced diagnostic gap: a critical barrier to leprosy elimination.
PMID:日期:2026-08-29该文献暂无摘要。
-
8. Clinical practice guideline for psoriasis management in Latin America.
PMID:日期:2026-08-29Psoriasis care in Latin America is heterogeneous, and access to systemic agents, biologics, phototherapy, and monitoring resources varies widely across countries. To develop a regional, evidence-based clinical practice guideline for psoriasis management using GRADE methodology. The Latin American Psoriasis Society (SOLAPSO) convened a guideline development group, an extended expert panel, patients, and an independent methodological team. We framed clinical questions using PICO, conducted systematic literature reviews, rated certainty of evidence with GRADE, and formulated recommendations through structured Evidence-to-Decision deliberations incorporating benefits and harms, patient values, feasibility, equity, and resource use. Independent external reviewers assessed clarity and methodological quality. The guideline provides measurable therapeutic targets for plaque psoriasis and key phenotypes, including nail psoriasis, generalized pustular psoriasis, and other special forms. It recommends first-line conventional systemic options (methotrexate, cyclosporine, acitretin) and phototherapy, and it defines indications for escalation to biologic agents or small molecules after inadequate response, intolerance, or contraindications to conventional therapy. It addresses selection across biologic classes, use of biosimilars, and strategies for primary and secondary therapeutic failure. Additional recommendations cover high-impact areas (scalp, nails, palmoplantar, inverse, genital) and special situations (pregnancy, cancer, chronic viral infections, HIV, latent tuberculosis, pediatric psoriasis), plus nonpharmacologic interventions (weight reduction and structured psychological support). Limitations include heterogeneity in the availability of regional evidence, indirect evidence for some special populations, and variability in access to therapies across Latin American health systems. This guideline offers an actionable framework for comprehensive psoriasis care in Latin America, balancing best available evidence with regional constraints to support equitable, patient-centered implementation in routine clinical practice.
-
10. Beyond stigma: integrating social and diagnostic determinants of delayed leprosy detection.
PMID:日期:2026-08-29该文献暂无摘要。